The ATTRibute-CM study's open-label extension showed that acoramidis effectively lowers all-cause mortality in patients with ...
Findings from a prospective phase 2 clinical trial show that isatuximab (Sarclisa), an anti-CD38 monoclonal antibody, is an effective and well-tolerated treatment for patients with relapsed and/or ...
ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart failure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback